Biotech Firms Spot Opportunity As Baby-Boomer Generation Ages

Generation Ages Author: Karen Young Kreeger Date: February 19, 1996 As the baby-boomer generation gets older, biotech companies are stepping up their research efforts with the goal of capitalizing on the huge potential market for anti-aging products. The number of drugs and therapies in development for diseases of the elderly increased from 125 in 1993 to 132 in July 1995. The number of companies developing those remedies climbed from 60 to 71 in the same time frame, according to New Medicines

Written byKaren Young Kreeger
| 8 min read

Register for free to listen to this article
Listen with Speechify
0:00
8:00
Share

Generation Ages Author: Karen Young Kreeger
Date: February 19, 1996

As the baby-boomer generation gets older, biotech companies are stepping up their research efforts with the goal of capitalizing on the huge potential market for anti-aging products. The number of drugs and therapies in development for diseases of the elderly increased from 125 in 1993 to 132 in July 1995. The number of companies developing those remedies climbed from 60 to 71 in the same time frame, according to New Medicines in Development for Older Americans (Pharmaceutical Research and Manufacturers of America [PhRMA], Washington, D.C., 1995).

No Voodoo Science: Understanding the aging process is no longer the stuff of science fiction, says Daniel Perry. And last fall, experts in a number of fields assembled by Batelle Memorial Institute, a consulting firm in Columbus, Ohio, listed anti-aging products and devices seventh on a top-10 list of technologies most likely to bring ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies